The global contact lenses market size is projected to reach USD 12.05 billion by 2026, exhibiting a CAGR of 4.8% during the forecast period. However, the market was worth USD 8.35 billion in 2018. This information is published in a recent report by Fortune Business Insights, titled, “Contact Lenses Market Size, Share & Industry Analysis, By Modality (Reusable and Disposable), By Design (Toric, Multi-Focal, and Spherical), By Distribution Channel (Retail Stores, Online Stores, and Ophthalmologists), and Regional Forecast, 2019-2026.” As per the report, rising per capita healthcare expenditure and increasing incidence of astigmatism and myopia are expected to affect the market positively.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contact-lenses-market-101775

Fortune Business Insights lists out some of the renowned companies operating in the contact lenses market. They are as follows:

• Contamac
• CooperVision
• HOYA Corporation
• Essilor
• Bausch & Lomb Incorporated
• Johnson & Johnson Vision Care, Inc. (Johnson & Johnson Services, Inc.)
• ZEISS International
• Alcon Vision LLC
• Other key market players

Rising Prevalence of Ocular Disorders to Augment Market Growth

The World Health Organization (WHO) stated that approximately 1.7 million people are affected by presbyopia and around 153 million people reside with uncorrected refractive errors around the world. A rising prevalence of presbyopia worldwide is one of the main factors propeling the contact lenses market growth in the coming years. Also, many people are affected by ocular disorders, which in turn, is expected to boost growth of the market.

Spherical Segment to Dominate the Market Backed by High Prescriptions

In terms of design, the market is segregated into spherical, multifocal, and toric. Out of these, the spherical segment had generated 65.8% contact lenses market share in 2018 and was in the leading position. It occurred because these lenses are highly recommended by doctors for correcting ocular disorders. The toric segment, on the other hand, is anticipated to showcase considerable growth owing to its possession of numerous advantages, such as greater lens-to-lens reproducibility, easier fitting protocol, and better stabilization design. Lastly, the multifocal segment would expand at faster pace in the near future due to growing awareness and increasing new product launches.

The global e-prescribing market size is expected to touch USD 4,017.79 million by the end of 2026, attributable to the incorporation of e-prescribing software in the Electronic Health Record (EHR) solutions. E-prescribing or electronic prescribing is a new technologic infrastructure that helps the medical professionals to write and send prescriptions directly to the pharmacy. Fortune Business Insights, in its recent report, titled, “E-prescribing Market Size, Share & Industry Analysis, By Delivery Mode (Web-based, On-premise), By Prescription Type (Controlled substance, Non controlled Substances) By End User (Hospitals, Physician’s offices, Pharmacies) and Regional Forecast, 2019-2026,” states that the value of the market was USD 863.64 million in 2018 and will exhibit a CAGR of 21.0% during 2019 to 2026.

Please visit: 

https://www.fortunebusinessinsights.com/e-prescribing-market-102698

The rising prevalence of unwanted pregnancies is boosting the global contraceptive drugs market. In a report, titled “Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025” Fortune Business Insights identifies various factors enabling growth in the market.

Leading Players operating in the Contraceptive Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Bayer AG

• Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc
• Agile Therapeutics
• Piramal Enterprises Ltd

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contraceptive-drugs-market-100063

According to the report, the global contraceptive drugs market is anticipated to rise at 5.8% CAGR and reach a value of US$ 20,200.5 Mn by 2025 from US$ 13,097.7 Mn in 2017. Remarkably improving access to contraceptive pills around the world is a key factor propelling growth in this market.

Rising Abortion Rates to Create Demand for Contraceptive Drugs

Under the Affordable Care Act (ACA) in the U.S., oral contraceptive pills are given free of cost to women in the U.S. Such regulations favor the growth of the contraceptive drugs market. Increasing government initiatives to reduce infant mortality due to early pregnancies will increase the demand for oral contraceptives. Contraceptive drugs not only help to control unwanted pregnancies but also reduce the number of abortion and complications associated with the procedure worldwide. As per the World Health Organization, there is an estimated 40 to 50 million abortions every year, corresponding to an approximate of 125,000 abortions per day. To avoid unwanted and unplanned pregnancies, an increasing number of women are opting for contraceptive drugs. This will in turn augment growth in the global market.

Government Initiatives to Promote Use of Contraceptive Medicines

Geographically, North America held dominance in the global contraceptive drugs market owing to the presence of leading players in the region. This, accompanied with easy availability of contraceptive drugs, has catapulted North America to the fore of the global market. However, Asia Pacific is most likely to emerge as the fastest growing region. This is owing to government initiatives adopted across emerging nations of this region. These initiatives are intended at promoting the use of contraceptive medicines as a convenient way of preventing unwanted pregnancy.

According to Fortune Business Insights, the global contraceptive drugs market has a highly fragmented vendor landscape. This is because of the presence of both regional and international players. Major players are focusing on expanding their footprint across the world to gain a strong foothold in the market. Manufacturers are also putting efforts to improve their product visibility especially in developing economies with new marketing strategies. This is likely to make the competition fiercer as manufacturers are investing huge sums into research and development.

The rising prevalence of unwanted pregnancies is boosting the global contraceptive drugs market. In a report, titled “Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025” Fortune Business Insights identifies various factors enabling growth in the market.

Leading Players operating in the Contraceptive Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Bayer AG

• Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc
• Agile Therapeutics
• Piramal Enterprises Ltd

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contraceptive-drugs-market-100063

According to the report, the global contraceptive drugs market is anticipated to rise at 5.8% CAGR and reach a value of US$ 20,200.5 Mn by 2025 from US$ 13,097.7 Mn in 2017. Remarkably improving access to contraceptive pills around the world is a key factor propelling growth in this market.

Rising Abortion Rates to Create Demand for Contraceptive Drugs

Under the Affordable Care Act (ACA) in the U.S., oral contraceptive pills are given free of cost to women in the U.S. Such regulations favor the growth of the contraceptive drugs market. Increasing government initiatives to reduce infant mortality due to early pregnancies will increase the demand for oral contraceptives. Contraceptive drugs not only help to control unwanted pregnancies but also reduce the number of abortion and complications associated with the procedure worldwide. As per the World Health Organization, there is an estimated 40 to 50 million abortions every year, corresponding to an approximate of 125,000 abortions per day. To avoid unwanted and unplanned pregnancies, an increasing number of women are opting for contraceptive drugs. This will in turn augment growth in the global market.

Government Initiatives to Promote Use of Contraceptive Medicines

Geographically, North America held dominance in the global contraceptive drugs market owing to the presence of leading players in the region. This, accompanied with easy availability of contraceptive drugs, has catapulted North America to the fore of the global market. However, Asia Pacific is most likely to emerge as the fastest growing region. This is owing to government initiatives adopted across emerging nations of this region. These initiatives are intended at promoting the use of contraceptive medicines as a convenient way of preventing unwanted pregnancy.

According to Fortune Business Insights, the global contraceptive drugs market has a highly fragmented vendor landscape. This is because of the presence of both regional and international players. Major players are focusing on expanding their footprint across the world to gain a strong foothold in the market. Manufacturers are also putting efforts to improve their product visibility especially in developing economies with new marketing strategies. This is likely to make the competition fiercer as manufacturers are investing huge sums into research and development.

The rising prevalence of unwanted pregnancies is boosting the global contraceptive drugs market. In a report, titled “Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025” Fortune Business Insights identifies various factors enabling growth in the market.

Leading Players operating in the Contraceptive Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Bayer AG

• Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc
• Agile Therapeutics
• Piramal Enterprises Ltd

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contraceptive-drugs-market-100063

According to the report, the global contraceptive drugs market is anticipated to rise at 5.8% CAGR and reach a value of US$ 20,200.5 Mn by 2025 from US$ 13,097.7 Mn in 2017. Remarkably improving access to contraceptive pills around the world is a key factor propelling growth in this market.

Rising Abortion Rates to Create Demand for Contraceptive Drugs

Under the Affordable Care Act (ACA) in the U.S., oral contraceptive pills are given free of cost to women in the U.S. Such regulations favor the growth of the contraceptive drugs market. Increasing government initiatives to reduce infant mortality due to early pregnancies will increase the demand for oral contraceptives. Contraceptive drugs not only help to control unwanted pregnancies but also reduce the number of abortion and complications associated with the procedure worldwide. As per the World Health Organization, there is an estimated 40 to 50 million abortions every year, corresponding to an approximate of 125,000 abortions per day. To avoid unwanted and unplanned pregnancies, an increasing number of women are opting for contraceptive drugs. This will in turn augment growth in the global market.

Government Initiatives to Promote Use of Contraceptive Medicines

Geographically, North America held dominance in the global contraceptive drugs market owing to the presence of leading players in the region. This, accompanied with easy availability of contraceptive drugs, has catapulted North America to the fore of the global market. However, Asia Pacific is most likely to emerge as the fastest growing region. This is owing to government initiatives adopted across emerging nations of this region. These initiatives are intended at promoting the use of contraceptive medicines as a convenient way of preventing unwanted pregnancy.

According to Fortune Business Insights, the global contraceptive drugs market has a highly fragmented vendor landscape. This is because of the presence of both regional and international players. Major players are focusing on expanding their footprint across the world to gain a strong foothold in the market. Manufacturers are also putting efforts to improve their product visibility especially in developing economies with new marketing strategies. This is likely to make the competition fiercer as manufacturers are investing huge sums into research and development.

The global compression therapy market size is projected to reach USD 4.51 billion by 2026, exhibiting a CAGR of 5.2% during the forecast period. Rising prevalence of cancer will be a key growth driver for this market in the coming decade, finds Fortune Business Insights™ in its report, titled “Compression Therapy Market Size, Share and Industry Analysis By Product (Compression Garments {Compression Bandages, Compression Stockings, and Others}, Compression Pumps, and Others), By Application (Venous Leg Ulcer, Deep Vein Thrombosis (DVT), Lymphedema, and Others), By End User (Hospitals & Clinics, Nursing Care Centers, Home Care, and Others), and Regional Forecast, 2019-2026”. The global disease burden of cancer, according to the International Agency for Research on Cancer (IARC), rose by an estimated 18.1 million new cases in 2018.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/compression-therapy-market-102689

List of Top Players Covered in the Report:

• Tactile Systems Technology, Inc.
• Smith & Nephew
• medi GmbH & Co. KG
• Arjo
• SIGVARIS
• Bio Compression Systems, Inc.
• EssityAktiebolag (publ)
• PAUL HARTMANN Pty. Ltd
• 3M

Cancer therapy, especially for breast and prostate cancers, generally involves dissection of lymph nodes, which causes disruption in the filtering mechanism of the lymphatic system in the body. As a result, lymph fluid accumulates and causes massive swelling of limbs or tissues, a condition known as lymphedema. Worldwide prevalence of this condition, as reported by the National Institutes of Health, is around 250 million. One of the most commonly used treatment options for lymphedema is compression therapy and with increasing incidence of this condition, the demand for these therapies is set to steadily rise.

Regional Analysis

Healthy R&D Funding to Fuel the Market in North America

The market size in North America stood at USD 1.05 billion in 2018 backed by concerted investment in healthcare research and development by the private and public sectors. In addition to that, rising geriatric population and strong presence of global companies is anticipated to aid the region to dominate the compression therapy market share during the forecast period. In Europe, the primary growth propeller will be the development and launch of innovative products by players in the region. On the other hand, steadily increasing number of patients with lymphatic and venous conditions is expected to augur well for the market in Asia-Pacific.

Competitive Landscape

Focused Investment in Innovate to Heat Up Competition

One of the leading compression therapy market trends is the high priority that key companies in this market are giving to R&D and innovation. This intense focus on creating novel solutions for increasingly complex health issues is enabling these players to strengthen their market presence and broaden their range of offerings.

According to the World Bank, approximately 84% populace in Germany depend on Internet and around 75% populace in the U.S. are subscribers of the Internet, which augments the global ePharmacy market growth. Fortune Business Insights states that the global ePharmacy market is projected to reach US$ 177,794.9 Mn by 2026, thereby exhibiting an impressive CAGR of 17.3% during the forecast period (2019-2026). The company further states that the global market was valued at US$ 49,727.7 Mn in 2018. According to a published report by Fortune Business Insights, titled, “ePharmacy: Global Market Analysis, Insights and Forecast, 2019-2026,” the global ePharmacy market will witness notable growth during the forecast period due to the technological advancements based on artificial intelligence.

Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/epharmacy-market-100238

Fortune Business Insights has profiled some of the prominent market players operating in the global ePharmacy market. They are as follows:

• DocMorris
• CVS Health Corporation
• Express Script Holding Company
• Walgreen Co.
• Optum Rx, Inc.
• Giant Eagle, Inc.
• Walmart Stores, Inc.
• Rowland Pharmacy
• The Kroger Co.
• Other players

Increasing Adoption of E-commerce Websites to Favor Growth in Asia Pacific

Geographically, the global ePharmacy market is grouped into Asia Pacific, North America, the Middle East and Africa, Europe, and Latin America. Out of these regions, North America is expected to remain in the leading position in the global ePharmacy market during the forecast period. The growth is attributed to the rapid shift of consumers towards online retailers from offline pharmacies. Also, increasing usage of smartphones and high speed of the Internet are expected to aid North America in gaining the highest global ePharmacy market share in the forthcoming years. Furthermore, a rise in geriatric population, increasing online orders, and growing adoption of online platforms will drive the market growth in this region.

Europe and Asia Pacific, on the other hand, are projected to exhibit significantly high CAGR during the forecast period. In Europe, numerous prominent market players have begun offering products at lucrative rates. This will positively impact growth of ePharmacy market in this region. Asia Pacific, on the other hand, has been witnessing higher adoption of e-commerce websites and increasing patient pool. Moreover, the healthcare infrastructure in this region is on the verge of becoming prosperous. All these factors are anticipated to fuel ePharmacy market growth in Asia Pacific in the coming years.

Key Market Players to Focus on Bagging Funds for Expanding Online Platforms 

Several key market players operating in the global ePharmacy market have begun exploring and implementing new strategies to provide the consumers with smooth service. Fortune Business Insights has listed a few key developments that have occurred in the global ePharmacy market since the past few years:

• Meds, a Swedish online pharmacy announced in January 2019 that it raised US$ 5.5 million in a funding round conducted by Inbox Capital, a family-owned venture capital company, headquartered in Sweden. The total amount of the startup has increased to US$ 10.5 million. Meds sells healthcare, beauty products, prescription, and non-prescription drugs. They have received permission from the Swedish Medical Product Agency to sell those. According to the company, approximately 40% of the sales come from the households in the Stockholm area as the home delivery service takes less than two hours. After receiving the funds, the company declared that it would soon expand their area of delivery to both Gothenburg and Malmö. Also, the company has planned to expand its warehouse area.

The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, “Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing Autoimmune Myopathy (NAM), Others), By Treatment (Corticosteroids, Immunosuppressants, Intravenous Immunoglobulins, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026.”

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/idiopathic-inflammatory-myopathy-treatment-market-100198

Fortune Business Insights™ profiles some of the most renowned companies present in the idiopathic inflammatory myopathy treatment market. They are as follows:

• Grifols, S.A.
• ImmunoForge
• Shire (Takeda Pharmaceutical Company Limited)
• ORPHAZYME A/S
• Mylan N.V.
• Biotest AG
• Pfizer Inc.
• CSL Limited (CSL Behring)
• LFB Group
• Kedrion S.p.A.
• Other key market players

Key Takeaways from the Report

• Quick outlook of the market entropy, such as new product launches, collaborations, deals, mergers and acquisitions, and agreements of key players.
• Elaborate information about the idiopathic inflammatory myopathy treatment market trends, growth aspect, complication, opportunities, and challenges.
• In-depth details of the performance of competitors.

Urgent Need for Modern Therapeutics to Boost Growth

Nowadays, numerous new, modern therapies are emerging across the world. The demand for more effective therapeutics is also rising day by day. Earlier, the traditional treatment options had limitations for the doses of immunosuppressants and glucocorticoids. They could be used up to a certain extent. However, today’s innovative therapeutic options help in treating a wide range of myositis.

Moreover, as more and more difficult-to-treat cases of idiopathic inflammatory myopathy increased, mankind realized the dire need for state-of-the-art therapies. It further created a high unmet demand for treatment options. It is expected to be one of the most crucial idiopathic inflammatory myopathy treatment market growth drivers.

The global hereditary angioedema treatment market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017. The global market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164

some of the key players in the global Hereditary Angioedema Treatment Market:

• BIOCRYST PHARMACEUTICALS INC.
• Ionis Pharmaceuticals Inc.
• Attune Pharmaceuticals
• Arrowhead Pharmaceuticals Inc.
• Adverum

According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute the expansion of the hereditary angioedema treatment market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, increasing number of product innovations in the region backed by high presence of hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the hereditary angioedema treatment market.

C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period

In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.

Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.

Shire, CSL Behring, and Pharming Group NV to Lead the Global Market

The global hereditary angioedema treatment market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.

The Global “Pulse Oximeters” Market is likely to grow in the coming years due to increasing usage clearances from the Food and Drug Administration (FDA). According to a report published by Fortune Business Insights, titled “Pulse Oximeters: Global Market Analysis, Insights and Forecast, 2018-2025,” the market is likely to reach US$ 2,657.6 Mn by the end of 2025. Fortune Business Insights states that the market was valued at US$ 1,587.3 Mn in 2017 and will exhibit a CAGR of 6.7% in the forecast period.

Leading Players operating in the Pulse Oximeters Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Omron Healthcare, Inc.
• Philips Benelux
• General Electric Manufacturing Company (GEMAC)
• Masimo
• Messe Düsseldorf GmbH
• Vyaire Medical
• Opto Circuits India Ltd.
• Medtronic
• Nonin Medical, Inc

Please visit: https://www.fortunebusinessinsights.com/industry-reports/pulse-oximeters-market-100528

iHealth’s Wristworn Pulse Oximeter to Witness Massive Demand

iHealth’s wrist-worn pulse oximeter’s wide end user coverage can be attributed to its clinical efficacy and most importantly, its ease of use. The device is available on e-commerce websites such as Amazon and the ease of availability for iHealth’s latest device is a leading factor that has contributed to the growth of the global market.

The device can continuously monitor blood oxygen saturation levels along with the pulse rate, both within a short span of time. The device is integrated with a LED display that shows the oxygen saturation readings. The device operated through the emission of infrared light onto the blood vessels of the fingertip. The device has won over many users and the increasing demand has led to the distribution on online retail chains as well as offline stores. iHealth’s latest device is likely to boost the global pulse oximeter market in the forthcoming years.

Market Segmentation:

By Product Type

• Fingertip Oximeters
• Handheld Oximeters
• Tabletop Oximeters

By End User

• Hospitals
• Ambulatory Surgery Centers and Clinics
• Home Healthcare
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Masimo’s Approval for Radius PPG to Trigger Growth

In 2019, Masimo received clearance for its latest pulse oximeter. The ‘Radius PPG’ was approved by the FDA after establishing efficient results through clinical trials. The Radius PPG represents a significant breakthrough in the healthcare industry, particularly for the diagnosis and study of oxygen levels in the blood. The wireless ability allows users to move freely even when they are being examined with the device.